Selective ERK1/2 agonists isolated from Melia azedarach with potent anti-leukemic activity

MAPK/ERK kinases transmit signals from many growth factors/kinase receptors during normal cell growth/differentiation, and their dysregulation is a hallmark of diverse types of cancers.